... Driven by the availability of Merck KGaA's Mavenclad and substantial uptake of Biogen's Tecfidera, the oral disease-modifying therapy (DMT) class share of DMT-treated multiple sclerosis ...
... development work in SMA CAMBRIDGE, Mass., Oct. 06, 2018 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced new interim results from NURTURE, an ongoing ...
... was promoted to medical director, and a year after that, she joined Biogen as director of clinical research. Biogen made Brennan senior director of medical ...
... program for progressive supranuclear palsy and BIIB054 program for Parkinson's disease highlight Biogen's commitment to furthering movement disorders research - Biogen's Phase 2 PASSPORT study ...
... PTC Therapeutics has presented clinical data on its Roche-partnered rival to Biogen and Ionis' spinal muscular atrophy (SMA) drug Spinraza. The interim readout shows ...
... for Treatment and Research in MS in Berlin, Germany (ECTRIMS; 112 October), Biogen Inc. (Nasdaq: BIIB) will present data in more than 70 oral and ...
... the role of medical director, and a year after that she joined Biogen as director of clinical research. Brennan found her background as an endocrinologist ...
... for the treatment of inflammatory and neurological indications. The Company granted to Biogen an irrevocable license to all of its IP through the Settlement and ...
... Therapy Market 2018-2022: Market to Grow at a CAGR of 22.42% with Biogen, Gilead, Novartis, Orchard Therapeutics & Spark Therapeutics Dominating ...
